Understanding Clinical Trials HR = 0.60 (CI : 0.51–0.70) p<0.0001

First Page		Document Content
Date: 2014-05-27 02:22:43 Research Clinical research Clinical trials Epidemiology End point of clinical trials Clinical endpoint Response Evaluation Criteria in Solid Tumors TroVax Bevacizumab Medicine Medical statistics Health		Understanding Clinical Trials HR = 0.60 (CI : 0.51–0.70) p<0.0001 Add to Reading List Source URL: www.roche.com Download Document from Source Website File Size: 2,36 MB Share Document on Facebook

	2011 Annual Report 20 years of GI Cancer Research DocID: Ya27 - View Document
	FO R U M DISCRIMINATING FACTORS IN TREATMENT DECISIONS FOR CHEMOTHERAPY IN ELDERLY PATIENTS WITH COLORECTAL CANCER DocID: XV8b - View Document
	Reproduced from Expert Review of Anticancer Therapy, December 2009, Vol. 9, No. 12, Pages[removed]with permission of Expert Reviews Ltd Editorial For reprint orders, please contact [removed] DocID: S7Ta - View Document
	Understanding Clinical Trials HR = 0.60 (CI : 0.51–0.70) p<0.0001 DocID: PbkO - View Document
	Understanding Clinical Trials HR = 0.60 (CI : 0.51–0.70) p<0.0001 DocID: OK0Z - View Document